AngioDynamics, Inc. announced enrollment of the first patient in the AMBITION BTK study of the Auryon atherectomy system.

The company reported revenue of $37.2 million in the first quarter, up 39% year over year, but said it has faced challenges ...

AngioDynamics (Nasdaq:ANGO) announced today that it enrolled the first patient in a randomized study of its Auryon ...

Five Dogs of the Dow stocks offer big yields, a degree of safety from tariffs, and a long history of corporate success.

Impact of prognostic scores on acute kidney injury assessment in the postoperative period of myocardial revascularization ...

Coronary heart disease is an important source of mortality and morbidity among kidney transplantation and liver transplantation candidates and recipients and is driven by traditional and ...

Perfuze, an Ireland-based developer of catheters for interventional stroke care, recently announced preliminary results from ...

Millipede88 Aspiration Catheter, Perfuze’s Flagship Superbore Aspiration Catheter The trial is evaluating the safety and ...

European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months ...

Detailed price information for Angiodynamics Inc (ANGO-Q) from The Globe and Mail including charting and trades.

NEW YORK, NY, USA I July 24, 2025 I GNT Pharma, a late-stage biopharmaceutical company with operations in Seoul and New York, today announced its IND ...

Despite an increase in the conversion factor, slashed payments elsewhere could amount to “death by a thousand paper cuts.” ...